|
26 Feb 2020 |
NIH clinical trial of remdesivir to treat COVID-19 begins
|
|
26 Feb 2020 |
Vanda Reports results from the EPIONE study of Tradipitant in the treatment of Pruritus in Atopic Dermatitis
|
|
25 Feb 2020 |
Spring Bank Announces Clinical Collaboration to Evaluate SB 11285 in Combination with PD-L1 Checkpoint Inhibitor in Patients with Advanced Solid Tumors
|
|
25 Feb 2020 |
FDA Grants IND Approval to Promising Anti-Cancer Agent Veyonda®
|
|
24 Feb 2020 |
Ascentage Pharma Announces Approval for the Phase Ib/II Clinical Trial of APG-1387 in Combination with Chemotherapy for the Treatment of Advanced Pancreatic Cancer in China
|
|
24 Feb 2020 |
Magenta Therapeutics Completes Dosing in Phase 1 MGTA-145 Trial, Demonstrating Rapid, Single-Day First Line Stem Cell Mobilization and Collection
|
|
24 Feb 2020 |
Sojournix Announces Initiation of Phase 2 Clinical Trial of SJX-653, a Novel Selective NK3 Antagonist for Menopausal Hot Flashes
|
|
24 Feb 2020 |
U.S. FDA accepts GSK's sNDA application for Zejula (niraparib) for first-line maintenance treatment for women with platinum-responsive advanced ovarian cancer
|
|
24 Feb 2020 |
Takeda Announces U.S. FDA Grants Priority Review for Supplemental New Drug Application for ALUNBRIG® (brigatinib) as a First-Line Treatment for ALK+ Metastatic Non-Small Cell Lung Cancer
|
|
24 Feb 2020 |
United Therapeutics Announces INCREASE Study Of Tyvaso® Meets Primary And All Secondary Endpoints
|
|
22 Feb 2020 |
Esperion Announces FDA Approval of NEXLETOL™ (bempedoic acid) Tablet, an Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine
|
|
21 Feb 2020 |
AB Science announces positive top-line Phase 2B/3 results for oral masitinib in progressive forms of multiple sclerosis
|
|
20 Feb 2020 |
Cellectar Biosciences Announces CLR 131 Achieves Primary Efficacy Endpoints from Its Phase 2 CLOVER-1 Study in Relapsed/Refractory B-cell Lymphomas and Completion of the Phase 1 Relapsed/Refractory Multiple Myeloma Dose Escalation Study
|
|
20 Feb 2020 |
Cytokinetics Announces Preclinical Data for CK-3773274 Presented at the Biophysical Society 64th Annual Meeting
|
|
20 Feb 2020 |
DelMar Pharmaceuticals [Nasdaq:DMPI] Enrolls Final Patient in Phase 2 Clinical Trial of VAL-083 For First-Line Treatment of Brain Tumors
|
|
20 Feb 2020 |
Dyve Biosciences Announces First Patient Enrolled in TARGETS Study for Treatment of Acute Gout
|
|
20 Feb 2020 |
Terns Pharmaceuticals Announces Safety and Pharmacodynamic Results of a Phase 1 Clinical Trial of TERN-101, a Liver-Selective FXR Agonist in Development for the Treatment of NASH
|
|
20 Feb 2020 |
Teva Announces Registration Trials of Deutetrabenazine in Pediatric Patients with Tourette Syndrome Did Not Meet the Primary Endpoint
|
|
19 Feb 2020 |
Incyte Announces Positive Topline Results From Phase 3 TRuE-AD Program Evaluating Ruxolitinib Cream in Patients With Atopic Dermatitis
|
|
19 Feb 2020 |
U.S. Food and Drug Administration Accepts Karyopharm’s Supplemental New Drug Application for XPOVIO® (Selinexor) as a Treatment for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
|
|
18 Feb 2020 |
BioXcel Therapeutics Announces Initiation of a Phase 2 Study Designed to Assess Agitation-Associated Biomarkers and their Response to BXCL501
|
|
18 Feb 2020 |
FDA Accepts BioCryst’s NDA for Oral, Once Daily Berotralstat (BCX7353) to Prevent HAE Attacks
|
|
18 Feb 2020 |
European Commission Approves VYNDAQEL®, the First Treatment in the EU for Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
|
|
17 Feb 2020 |
PharmaMar and Jazz Pharmaceuticals Announce FDA Acceptance and Priority Review of New Drug Application for Lurbinectedin in Relapsed Small Cell Lung Cancer
|
|
16 Feb 2020 |
Morphic Presents Positive Preclinical Data Supporting MORF-057 as an Oral Inhibitor of the α4β7 Integrin and Potential Treatment for Inflammatory Bowel Disease
|
